BRIEF-Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma

Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc.

LYEL

0.00

June 12 (Reuters) - Lyell Immunopharma Inc LYEL.O:

  • LYELL IMMUNOPHARMA PRESENTS UPDATED SAFETY DATA AND TRANSLATIONAL INSIGHTS FOR RONDECABTAGENE AUTOLEUCEL (RONDE-CEL) IN PATIENTS WITH LARGE B-CELL LYMPHOMA AT EUROPEAN HEMATOLOGY ASSOCIATION 2026 CONGRESS

  • LYELL IMMUNOPHARMA - PINACLE PIVOTAL TRIAL DATA UPDATE EXPECTED H2 2026; BLA SUBMISSION PLANNED H2 2027

  • LYELL IMMUNOPHARMA - RONDE-CEL TREATED OVER 100 PATIENTS IN 2L AND 3L+ LBCL WITH 97% MANUFACTURING SUCCESS RATE

  • LYELL IMMUNOPHARMA - NO GRADE 3 OR HIGHER CRS AND LOW RATES OF GRADE 3 OR HIGHER ICANS REPORTED

Source text: ID:nGNX31vqLm

Further company coverage: LYEL.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.